智通财经APP获悉，周一，Xenon制药(XENE.US)开盘飙升超42%，报59.59美元。消息面上，3月9日，该公司公布Azetukalner治疗局灶性癫痫的3期X-TOLE2研究达到主要终点，25mg剂量组中位发作频率降低53.2%，安慰剂组为10.4%，p值0.000000000006。该公司确认Azetukalner安全性特征与前期研究一致，耐受性良好，并宣布计划于2026年第三季度向美国FDA提交Azetukalner的新药申请。此外，威廉博莱分析师Myles Minter维持Xenon制药买入评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.